Volume 18, Issue 11, Pages (November 2016)

Slides:

Advertisements

Similar presentations

Irreplaceability of Neuronal Ensembles after Memory Allocation Naoki Matsuo Cell Reports Volume 11, Issue 3, Pages (April 2015) DOI: /j.celrep

Advertisements

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals Xiang H.-F. Zhang, Qiongqing Wang, William Gerald, Clifford A. Hudis, Larry.

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

GI-NEUROENDOCRINE TUMORS THERAPEUTIC APROACHES Chemotherapy: older and recent schemes Ilias Athanasiadis, MD Medical Oncologist Director of the Oncology.

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells Roger R. Gomis, Claudio Alarcón, Cristina Nadal, Catherine.

Ex Vivo Gene Therapy Using Patient iPSC-Derived NSCs Reverses Pathology in the Brain of a Homologous Mouse Model Tagan A. Griffin, Hayley C. Anderson,

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

MiR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells Mathieu Neault, Frédérick A. Mallette, Stéphane Richard Cell.

Modeling Inducible Human Tissue Neoplasia Identifies an Extracellular Matrix Interaction Network Involved in Cancer Progression Jason A. Reuter, Susana.

Genetic testing for high-risk colon cancer patients1 William M. Grady Gastroenterology Volume 124, Issue 6, Pages (May 2003) DOI: /S (03)

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

A Conditional Mouse Model for Malignant Mesothelioma Johan Jongsma, Erwin van Montfort, Marc Vooijs, John Zevenhoven, Paul Krimpenfort, Martin van der.

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Volume 68, Issue 6, Pages (December 2015)

Expression Levels of KMT2C and SLC20A1 Identified by Information-theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

Volume 23, Issue 1, Pages (February 2014)

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

Volume 23, Issue 1, Pages (February 2014)

Volume 19, Issue 11, Pages (November 2017)

Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study.

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Chemotherapy and Cancer Stem Cells

Treatment of Malignant Pleural Effusion

Advances in the Treatment of Metastatic Prostate Cancer

Intravascular Survival and Extravasation of Tumor Cells

Volume 61, Issue 4, Pages (April 2012)

Increased MAPK1/3 Phosphorylation in Luminal Breast Cancer Related with PIK3CA Hotspot Mutations and Prognosis Diana Ramirez-Ardila, A. Mieke Timmermans,

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

New Views into the Genetic Landscape of Metastatic Breast Cancer

Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients

Volume 4, Issue 1, Pages 4-6 (July 2003)

Volume 71, Issue 6, Pages (June 2017)

Circulating tumor DNA: Solid data from liquid biopsies

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers Andrea.

Volume 26, Issue 2, Pages (February 2018)

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer Timothy R. Wassenaar, MD, Jens C.

It’s a SMAD/SMAD World Cell

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Allele-Specific, Non-Extendable Primer Blocker PCR (AS-NEPB-PCR) for DNA Mutation Detection in Cancer Haiying Wang, John Jiang, Bianca Mostert, Anieta.

Yibin Kang, Klaus Pantel Cancer Cell

Patricia Munoz-Garrido, Jesper B. Andersen Gastroenterology

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Volume 74, Issue 8, Pages (October 2008)

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Adverse Prognostic Factors for Morbidity and Mortality During Peripheral Blood Stem Cell Mobilization in Patients with Light Chain Amyloidosis Jason.

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous.

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Volume 163, Issue 4, (November 2015)

Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma Leila Khoja, Paul Lorigan, Cong Zhou, Matthew Lancashire, Jessica Booth,

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Razvan Diaconescu, MD, Chantal Lafond, MD, Renaud Whittom, MD

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC Phil A.J.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Volume 3, Issue 5, Pages (November 2017)

Presentation transcript:

Volume 18, Issue 11, Pages 647-653 (November 2016) Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor Nick Beije, Wendy Onstenk, Jaco Kraan, Anieta M. Sieuwerts, Paul Hamberg, Luc Y. Dirix, Anja Brouwer, Felix E. de Jongh, Agnes Jager, Caroline M. Seynaeve, Ngoc M. Van, John A. Foekens, John W.M. Martens, Stefan Sleijfer Neoplasia Volume 18, Issue 11, Pages 647-653 (November 2016) DOI: 10.1016/j.neo.2016.08.007 Copyright © 2016 The Authors Terms and Conditions

Figure 1 PFS and OS according to HER2-CTC status. (A and C) PFS and OS, respectively, for the endocrine therapy cohort. (B and D) PFS and OS, respectively, for chemotherapy cohort. Neoplasia 2016 18, 647-653DOI: (10.1016/j.neo.2016.08.007) Copyright © 2016 The Authors Terms and Conditions

Figure 2 PFS and OS according to ER-CTC status. (A and C) PFS and OS, respectively, for the endocrine therapy cohort. (B and D) PFS and OS, respectively, for chemotherapy cohort. Neoplasia 2016 18, 647-653DOI: (10.1016/j.neo.2016.08.007) Copyright © 2016 The Authors Terms and Conditions